MiNK Therapeutics (NASDAQ:INKT) Director Sells $20,020.00 in Stock

MiNK Therapeutics, Inc. (NASDAQ:INKT) Director Barbara Ryan sold 1,300 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $15.40, for a total value of $20,020.00. Following the sale, the director directly owned 20,406 shares of the company’s stock, valued at approximately $314,252.40. This trade represents a 5.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Barbara Ryan also recently made the following trade(s):

• On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $2,034.00.
• On Monday, March 2nd, Barbara Ryan sold 100 shares of MiNK Therapeutics stock. The stock was sold at an average price of $10.83, for a total value of $1,083.00.
• On Friday, February 27th, Barbara Ryan sold 400 shares of MiNK Therapeutics stock. The shares were sold at an average price of $10.86, for a total value of $4,344.00.

MiNK Therapeutics Stock Performance

Shares of NASDAQ:INKT opened at $9.74 on Friday. MiNK Therapeutics, Inc. has a 1 year low of $6.34 and a 1 year high of $76.00. The stock has a market capitalization of $45.68 million, a P/E ratio of -3.21 and a beta of 0.35. The stock has a 50-day simple moving average of $11.54 and a 200-day simple moving average of $12.71.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC increased its stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 2.87% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.